Phosphodiesterase Inhibitors : Alternative Treatment for Lower Urinary Tract Symptoms Caused by Benign Prostate Hyperplasia
DOI:
https://doi.org/10.53089/medula.v13i5.576Keywords:
BPH, DE, LUTS, PDE5-IsAbstract
Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) are often bothersome and hinder the quality of life for eldery. The incidence of BPH in Indonesia, namely at Cipto Mangunkusumo Hospital from 1994-2013, found 3,804 cases with an average age of patients 66.61 years. Adrenoceptor antagonists (α‑blockers, ABs) and 5-Alpha reductase Inhibitors (5-ARIs) are recommended first-line treatment for LUTS due to BPH. Although effective, these medications may have adverse effects, including dizziness, hypotension, and sexual dysfunction. Phosphodiesterase 5 Inhibitors (PDE5-Is) have been used globally as first-line drugs for erectile dysfunction. The first study in 2002 reported that PDE5‑Is could improve urinary tract symptom scores in patients w
References
Yamaguchi O. Latest treatment for lower urinary tract dysfunction: Therapeutic agents and mechanism of action. International Journal of Urology. 2013;20(1):28-39.
Jinak PP, Rainy CAM, Doddy U, et al. Panduan Penatalaksanaan Klinis.; 2015.
Wang XH, Wang X, Shi MJ, Li S, Liu T, Zhang XH. Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH. Asian J Androl. 2015;17(6):1022-1032.
Kim EH, Brockman JA, Andriole GL. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J Urol. 2018;5(1):28-32.
Wang X, Wang X, Li S, Meng Z, Liu T, Zhang X. Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: A systematic review and network meta-Analysis. PLoS One. 2014;9(9).
Zhang X, Zang N, Wei Y, et al. Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling Downloaded from. Am J Physiol Endocrinol Metab. 2012;302:243-253.
Pattanaik S, Panda A, Mathew JL, et al. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews. 2018;2018(11).
He W, Xiang H, Liu D, et al. Changes in the expression and function of the PDE5 pathway in the obstructed urinary bladder. J Cell Mol Med. 2020;24(22):13181-13195.
Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118-140.
Dahm P, Brasure M, MacDonald R, et al. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Eur Urol. 2017;71(4):570-581.
Silva J, Silva CM, Cruz F. Current medical treatment of lower urinary tract symptoms/BPH: Do we have a standard? Curr Opin Urol. 2014;24(1):21-28.
Kim SW, Park NC, Lee SW, et al. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial. Journal of Sexual Medicine. 2017;14(8):1018-1027.
Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: Analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies. Journal of Sexual Medicine. 2013;10(8):2044-2052.
Zhang J, Li X, Yang B, Wu C, Fan Y, Li H. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. World J Urol. 2019;37(1):143-153.
Pattanaik S, Mavuduru RS, Panda A, et al. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. BJU Int. 2019;124(1):27-34.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Medical Profession Journal of Lampung
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
